BEIJING, Nov. 22 (Xinhuanet) -- China's drug watchdog
Tuesday approved its home-made human bird flu vaccine for clinical test, a major
progress in China's prevention efforts of possible pandemic flu.
|Resercher displays human vaccines for bird
The vaccine was developed from
NIBRG-14 virus strain recommended and provided by the World Health Organization
(WHO), according to the State Food and Drug Administration (SFDA).
Pre-clinical trials show the vaccine is fairly safe
and effective and the virus strain and the producing procedures of the vaccine
are reliable, said SFDA experts.
China began developing epidemic flu vaccine last
year. SFDA has been monitoring the progress since its early stage. Fast-track
examination procedures was granted to the vaccine after SFDA received
application from the producer, according to SFDA.
Beijing-based vaccine producer Sinovac Biotech, the
first in the world to develop a SARS vaccine, applied to SFDA for clinical tests
of the human bird flu vaccine in October. At present, the mass production for
the vaccine is ready, said Yin Weidong, general manager of the company.
China has so far reported 21 bird flu outbreaks in
nine provinces, autonomous regions and municipalities, and has confirmed two
human cases of bird flu. One victim in east China's Anhui Province has died and
the other in central China's Hunan Province has recovered.
Currently, seven other drug firms in the world, like
those in the United States, the European Union and Japan, are also developing
vaccines of this kind. Enditem